GSK:NYSE
GSK plc
$46.27
arrow_downward
-1.39%(-0.65) 1D
$46.65
arrow_upward
+0.82% (+0.38)todayPre-market
Closed: Oct 13, 4:00:03 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
$47.09
High
$47.15
Low
$46.10
Mkt. cap
93.48B
Avg. vol.
4.15M
Volume
8.68K
Dividend
3.92%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
14.85
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.12
Beta
0.25
Shares outstanding
2.16B
No. of employees
67K
Open
$47.09
High
$47.15
Low
$46.10
Mkt. cap
93.48B
Avg. vol.
4.15M
Volume
8.68K
Dividend
3.92%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
14.85
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.12
Beta
0.25
Shares outstanding
2.16B
No. of employees
67K
News stories
From web sources and news partners
Belga Share
·
1 hour ago
Shifts put more than 1,200 jobs at risk at GSK in Belgium
Investing.com
·
1 hour ago
GSK plans to cut up to 1,217 jobs in Belgium - report
Euronext Markets: Real-time Stock Market Data | live
·
2 hours ago
GSK to cut up to 1,217 jobs in Belgium, L'Echo says
Kalkine Media
·
3 hours ago
Is GSK plc (LSE:GSK) Stock Gaining Ground This Week On A Cost-Cutting Drive And Strong Quarter?
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com